ArticleFrontiers in psychiatry2026
Pre-treatment serum extracellular vesicle-enriched microbiome profiles and SSRI treatment response in obsessive-compulsive disorder: a prospective naturalistic cohort study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The microbiome is emerging as an important component of brain-body communication and may influence treatment outcomes in psychiatric disorders. This naturalistic cohort study prospectively evaluated whether baseline microbiome abundance and composition of circulating bacterial extracellular vesicles (EVs) are associated with subsequent response to selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive-compulsive disorder (OCD). Methods: Thirty-two drug-naïve or medication-free patients with OCD were enrolled and assessed at baseline and at 12 weeks following the initiation of SSRI pharmacotherapy. Serum EV microbiome profiling was performed at baseline, before any pharmacological treatment was commenced, ensuring that all biological measurements reflect a pharmacologically unconfounded pre-treatment state. Good responders were defined as patients with a 35% or greater reduction in the Yale-Brown Obsessive-Compulsive Scale score at 12 weeks, while poor responders were defined as those with less than a 35% reduction. Baseline microbiome abundance and composition of circulating bacterial EVs in serum were compared between these groups. Results: Of the 32 participants, 29 completed the 12-week study. Based on the treatment response at 12 weeks, the OCD group was classified into 15 good responders (5 females) and 14 poor responders (7 females). The two groups did not differ significantly in age, sex, age of onset, baseline Y-BOCS or MADRS scores, or medication type. No significant differences in alpha or beta diversity were observed between the groups. Taxonomic analysis of pre-treatment serum EV profiles revealed a nominally higher relative abundance of the genus Conclusion: These results provide no statistically defensible evidence of a taxon-level microbiome difference between response groups, and the nominal
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.